Target intelligence / Profile preview

Bile acid elimination (None)

Target
None
Molecular classification
Other (biological process), Involves enzymes: e.g., sulfotransferase 2A1 (SULT2A1), Involves transporters: e.g., bile salt export pump (BSEP/ABCB11), Involves nuclear receptors: farnesoid X receptor (FXR), Involves nuclear receptors: pregnane X receptor (PXR), Involves nuclear receptors: constitutive androstane receptor (CAR)
01

Overview

"Bile acid elimination" refers broadly to the physiological processes by which excess or potentially toxic endogenous bile acids are rendered more water-soluble—primarily via conjugation with glycine/taurine and further modification such as sulfation—and then transported out of hepatocytes into the biliary system for eventual fecal excretion. This multi-step pathway involves several key proteins including hepatic enzymes like cholesterol 7α-hydroxylase for synthesis; sulfotransferases like SULT2A1 for detoxification; ATP-binding cassette transporters such as ABCB11/BSEP for canalicular secretion; and regulatory nuclear receptors including FXR that coordinate gene expression relevant to these steps. Disruption at any point can result in accumulation of toxic intermediates leading to liver injury or systemic disease states such as cholestasis. Pharmacologic agents may enhance this process by binding intestinal bile acids ("sequestrants") or modulating relevant enzymatic/nuclear receptor activity.[1][2][3][4][5]

Other names
Bile acid excretionBile acid detoxificationBile salt elimination
02

Mechanism of action

For drugs affecting this pathway: - Binding/sequestration of intestinal bile acids prevents their reabsorption. - Induction or inhibition of enzymes involved in conjugation/sulfation. - Modulation of nuclear receptors regulating expression of transporters/enzymes involved in bile acid metabolism/elimination[4][5].

03

Biological functions

Cholesterol homeostasisDetoxification of bile acidsLipid digestion supportRegulation of enterohepatic circulation
04

Disease associations

Cholestatic liver diseaseHypercholesterolemiaGallstone diseaseLiver injury due to impaired bile flow
05

Safety considerations

Malabsorption syndromes if excessive loss occurs.Fat-soluble vitamin deficiencies with chronic sequestrant use.Potential hepatotoxicity if elimination pathways are impaired.
06

Interacting drugs

Bile acid sequestrants (e.g., cholestyramine)

2 more in the full profile.

07

Biomarkers

Serum/fecal total bile acidsSulfated/conjugated vs. unconjugated bile acids in plasma or urine

Beyond the preview

Go deeper on Bile acid elimination (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bile acid elimination (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call